This is the pioneer product from bit.bio’s new ioDisease Model portfolio, a range of cells which have specific disease-associated mutations, that can replicate human diseases in vitro and can be ...
Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results